AlphaFold predicted structure
GMNN · O75496

Mean pLDDT
69.5/ 100
Low
209 residues
Confidence breakdown
- Very high(≥ 90)28%
- Confident(70–90)14%
- Low(50–70)40%
- Very low(< 50)18%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
geminin DNA replication inhibitor
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownFetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownSevere microcephaly
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownClefting
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownEar-patella-short stature syndrome
Meier-Gorlin syndrome
neurodegenerative disease
microcephalic primordial dwarfism
lysosomal storage disease
alcohol drinking
hereditary disease
early-onset non-syndromic cataract
Total congenital cataract
Posterior polar cataract
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Geminin
Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC) (PubMed:14993212, PubMed:20129055, PubMed:24064211, PubMed:9635433). It is degraded during the mitotic phase of the cell cycle (PubMed:14993212, PubMed:24064211, PubMed:9635433). Its destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle (PubMed:14993212, PubMed:24064211, PubMed:9635433). Inhibits histone acetyltransferase activity of KAT7/HBO1 in a CDT1-dependent manner, inhibiting histone H4 acetylation and DNA replication licensing (PubMed:20129055). Inhibits the transcriptional activity of a subset of Hox proteins, enrolling them in cell proliferative control (PubMed:22615398)
GMNN · O75496

Mean pLDDT
69.5/ 100
Low
209 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0